Nature Reviews Clinical Oncology, Published online: 24 March 2026; doi:10.1038/s41571-026-01143-0 This Comment describes the clinical significance of the Mammography Screening with Artificial Intelligence (MASAI) trial, which is, to the best of our knowledge, the first randomized trial of artificial intelligence-supported mammography interpretation to examine interval cancer as an outcome. This trial used artificial intelligence to assign single-reading versus double-reading of mammograms and found that this approach does not increase interval cancers in the Swedish population.
Nature Reviews Clinical Oncology published a clinical update in Oncology on 24 Mar 2026.
The item focuses on In what clinical settings are the MASAI trial results applicable?.
Review the original article for the full source wording and details.